Evidence map›Paper›PMID 34791524›Full record

ArticleInternational journal of colorectal disease2022

Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up.

E van Lingen, M E Tushuizen, M E J Steenhuis, T van Deynen, J Martens, D Diaz-Infante Morales, A E van der Meulen-de Jong, I Molendijk, S van der Marel, P W J Maljaars

Registry-linked trialOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in International journal of colorectal disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05987748 (The Clock Thickens), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05987748 naunknown statusnot on this mapstarted 2023, after this paper: background citation

The Clock Thickens: Morning or Evening Training for the Treatment of NAFLD? (TikTac Study)

TypeinterventionalSponsorLeiden University Medical CenterRan2023 to 2024Enrolled40ConditionsNon-Alcoholic Fatty Liver DiseaseArmsExercise training
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Gut microbiota in MAFLD: therapeutic and diagnostic implications.Therapeutic advances in endocrinology and metabolism · 2024
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

E van LingenDepartment of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands. e.van_lingen@lumc.nl.ORCID http://orcid.org/0000-0002-3927-0345
M E TushuizenDepartment of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
M E J SteenhuisDepartment of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
T van DeynenDepartment of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
J MartensDepartment of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
D Diaz-Infante MoralesDepartment of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
A E van der Meulen-de JongDepartment of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
I MolendijkDepartment of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
S van der MarelDepartment of Gastroenterology and Hepatology, Haaglanden Medical Center (HMC), The Hague, The Netherlands.
P W J MaljaarsDepartment of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Leiden University Medical Center · NLMedisch Centrum Haaglanden · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLiver steatosis is a frequently reported condition in patients with inflammatory bowel disease (IBD). Different factors, both metabolic and IBD-associated, are believed to contribute to the pathogenesis. The aim of our study was to calculate the prevalence of liver steatosis and fibrosis in IBD patients and to evaluate which factors influence changes in steatosis and fibrosis during follow-up.

methodsFrom June 2017 to February 2018, demographic and biochemical data was collected at baseline and after 6-12 months. Measured by transient elastography (FibroScan), liver steatosis was defined as Controlled Attenuation Parameter (CAP) ≥248 and fibrosis as liver stiffness value (Emed) ≥7.3 kPa. IBD disease activity was defined as C-reactive protein (CRP) ≥10 mg/l and/or fecal calprotectin (FCP) ≥150 μg/g. Univariate and multivariate regression analysis was performed; a p-value of ≤0.05 was considered significant.

resultsEighty-two out of 112 patients were seen for follow-up; 56% were male. The mean age was 43 ± 16.0 years, and mean BMI was 25.1 ± 4.7 kg/m

conclusionsThis study confirms the relatively high prevalence of liver steatosis and fibrosis in IBD patients. We demonstrate that active IBD at baseline is associated with both an increase in liver steatosis and fibrosis during follow-up.

Indexed as

Inflammatory Bowel DiseasesNon-alcoholic Fatty Liver DiseaseAdultFollow-Up StudiesHumansLiverLiver CirrhosisMaleMiddle AgedInflammatory bowel diseasesLiver fibrosisLiver steatosisNon-alcoholic fatty liver disease

Identifiers

PMID34791524
OpenAlexW3213029055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.